Minimum Power and Frequency of Repeated Low-level Red-light to Effectively Control Myopia Progression

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age8-10
SponsorShanghai Eye Disease Prevention and Treatment Center

About this trial

To explore the minimum power and frequency of Repeated Low-level Red-light (RLRL) to control myopia progression in low-myopic children aged 8-10 years, and the rebound effect of low-myopic children after discontinuation of RLRL with different combinations of power and frequency.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age: 8-10 years old

Low myopia: cycloplegic spherical equivalent refractions (SERs) range from -0.50 (inclusive) to -3.00 diopters (D) and astigmatism less than -2.5 D in either eye.

signed informed consent and was able to participate in the study

Disqualifiers

Secondary myopia, such as a history of retinopathy of prematurity or other neonatal diseases; syndromic myopia with a known genetic disorder or connective tissue disease, such as Stickler syndrome or Marfan syndrome

Strabismus or other binocular vision abnormalities

Cloudy refractive media: cloudy cornea, cataract or intraocular lens surgery

Eye diseases that affect retinal function: macular degeneration, diabetic retinopathy, retinal detachment, glaucoma or ocular hypertension, endophthalmitis, uveitis, optic neuropathy, etc.

Trial design

Design model

Sequential

Treatments tested in this trial

  • Repeated Low-level Red-light

    Device

    In addition to single vision spectacle lenses (SVS) with power for correcting distance refraction, the subjects used the prescribed power low-intensity red light treatment instrument for the prescribed number of treatments from Monday to Friday, with a 3-minute interval of 4 hours.

  • Red LED

    Device

    In addition to SVS with power for correcting distance refraction, red LED will be performed twice per school day with an interval of at least 4 hours, each treatment last 3 minutes.

Treatment groups

108 Participants
are divided into 9 treatment groups

9

Treatment groups

See each treatment group below.

Group A: Red light: 2.0 mW/twice dailyExperimental treatment 1 intervention
Group B: Red light: 2.0 mW/once dailyExperimental treatment 1 intervention
Group C: Red light: 1.0 mW/twice dailyExperimental treatment 1 intervention
Group D: Red light: 1.0 mW/once dailyExperimental treatment 1 intervention
Group E: Red light: 0.5 mW/twice dailyExperimental treatment 1 intervention
Group F: Red light: 0.5 mW/once dailyExperimental treatment 1 intervention
Group G: Red light: 0.3 mW/twice dailyExperimental treatment 1 intervention
Group H: Red light: 0.3 mW/once dailyExperimental treatment 1 intervention
Group I: Red LED: twice dailySham comparator 1 intervention

Trial outcomes

Primary outcomes

1

The incidence (%) of axial length increase ≤0.05mm after red light for 3 months measured by the IOL master

Incidence rate of axial length shortening \> 0.05 mm is characterized as the ratio of number of participants with axial length shortening greater than 0.05 mm to the total number.

Time frame
1 week, 1, 2, 3 months

Secondary outcomes

1

The incidence rates (%) of cycloplegic spherical equivalent refraction progressing ≥0.00 D after red light for 3 months measured by the autorefractor

Refraction with full cycloplegia is performed with an autorefractor. The data on spherical and cylindrical power and axis is automatically extracted from the autorefractor. The spherical equivalent power (D) is calculated as the spherical power (D) plus half of the cylindrical power (D).

Time frame
1 week, 1, 2, 3 months
2

Changes of axial length (mm) after discontinuation of red light for 1 months measured by the IOL master

Change of axial length is characterized as the difference between each follow-up visit and baseline values.

Time frame
4 months
3

Changes of cycloplegic spherical equivalent refraction (D) after discontinuation of red light for 1 months measured by the autorefractor

Change of cycloplegic spherical equivalent refraction is characterized as the difference between each follow-up visit and baseline values.

Time frame
4 months
4

Incidence (%) of self-reported adverse events by the quesionnaire including but not limited to glare, flash blindness, and afterimages

Incidence of self-reported adverse events is the rate of self-reported adverse events over a specified period for all the subjects.

Time frame
1 week, 1, 2, 3, 4 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.